Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2016.262 | A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2017.465 | A clinical trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma, with parallel study on baseline and serial change in the immune environment |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2015.072 | A Phase 3, Randomized, Double-blind,Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase | Dr. CHAN Stephen Lam |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2014.526 | A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with Folfiri 3 versus placebo in combination with Folfiri 3 in the treatment of patients with non resectable locally advanced or metastatic pancreatic cancer | Prof. CHAN Stephen Lam |
| 2016.730 | A study on thromboembolism in pancreatic cancer patients |
Dr. CHAN Stephen Lam 陳林 |
| 2014.404 | A Randomized Phase 2 Study of LY2157299 versus LY2157299 – Sorafenib Combination versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2016.016 | A phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
Dr. CHAN Stephen Lam 陳林 |
| 2016.393 | A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2015.581 | A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2021.605 | ORGAN-SPECIFIC RESPONSES TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A MULTINATIONAL MULTICENTER STUDY |
Prof. CHAN Stephen Lam 陳林教授 |
| 2022.216 | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106) |
Prof. CHAN Stephen Lam 陳林 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
| 2022.403 | A Phase 1/ 2a, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma |
Prof. CHAN Stephen Lam 陳林 |
| 2022.463 | A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene |
Prof. CHAN Stephen Lam 陳林 |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2022.175 | Sequential TransArterial chemoembolization and stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for downstaging hepatocellular carcinoma for hepatectomy |
Prof. CHAN Stephen Lam 陳林醫生 |
| 2022.007 | Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors in hepatocellular carcinoma: A proof-of-concept clinical trial |
Prof. CHAN Stephen Lam 陳林 |
| 2021.629 | RETROSPECTIVE NON-INTERVENTIONAL STUDY OF THE EFFECTIVENESS AND SAFETY OF LANREOTIDE AUTOGEL® AT A DOSE OF 120 MG ONCE EVERY 28 DAYS IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS (GEP-NETS) IN HONG KONG AND TAIWAN |
Prof. CHAN Stephen Lam 陳林教授 |
| 2021.428 | Survival analysis for prognostic factors in biliary tract cancer |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2020.568 | FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Dr. CHAN Stephen Lam 陳林 |
| 2023.423 | A Clinical Study of Consistency Evaluation on Patient-Derived Organoid in Predicting Treatment Response for Hepatobiliary and Pancreatic Cancer | Prof. CHAN Stephen Lam |
| 2023.345 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Prof. CHAN Stephen Lam 陳林 |
| 2023.103 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 1: Hepatocellular Carcinoma (HCC) | Prof. CHAN Stephen Lam |
| 2020.625 | A PHASE II, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER |
Dr. CHAN Stephen Lam 陳林 醫生 |
| 2023.104 | A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA) | Prof. CHAN Stephen Lam |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephen Lam |
| 2025.180 | An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab with Lenvatinib as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma | Prof. CHAN Stephen Lam |
| 2025.627 | A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion | Prof. CHAN Stephen Lam |
| 2024.239 | A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA | Prof. CHAN Stephen Lam |
| 2025.184 | A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01) | Prof. CHAN Stephen Lam |
| 2023.513 | A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE) | Prof. CHAN Stephen Lam |
| 2025.360 | Establishment of New Territories East Cluster Biliary Tract Cancer Database | Prof. CHAN Stephen Lam |
| 2025.149 | A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1) | Prof. CHAN Stephen Lam |
| 2024.646 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination with Atezolizumab plus Bevacizumab Compared with Placebo plus Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated with Systemic Therapy | Prof. CHAN Stephen Lam |
| 2024.003 | A retrospective study on the outcome of patients with pancreatic neuroendocrine tumour in a regional setting | Prof. CHAN Stephen Lam |
| 2025.605 | A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors | Prof. CHAN Stephen Lam |
| 2025.306 | A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma (CADILYZE™ 202) | Prof. CHAN Stephen Lam |
| 2025.554 | Treatment and prognosis of patients with cancer: a Hong Kong-wide cohort study | Prof. CHAN Stephen Lam |
| 2024.724 | An Open-Label Phase 1/2 Study of WGI-0301 Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma as Second Line Therapy |
Prof. CHAN Stephen Lam 陳林 |
| 2023.567 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | Prof. CHAN Stephen Lam |
| 2024.379 | Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements | Prof. CHAN Stephen Lam |
| 2025.660 | A PHASE 2/3, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY OF ZANZALINTINIB VS EVEROLIMUS IN PARTICIPANTS WITH PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NEUROENDOCRINE TUMORS | Prof. CHAN Stephen Lam |
| 2024.098 | Establishment of a Hepatocellular Carcinoma Database | Prof. CHAN Stephen Lam |
| 2024.710 | DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer | Prof. CHAN Stephen Lam |
| 2024.368 | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER) | Prof. CHAN Stephen Lam |
| 2024.253 | A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol | Prof. CHAN Stephen Lam |
| 2026.296 | A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Participants with Advanced Solid Tumors | Prof. CHAN Stephen Lam |
Page 64 of 289.